Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH) Followed by an Open-label Extension

NCT07500090 is registered in ClinicalTrials.gov with Harmony Biosciences Management, Inc. as lead sponsor.

NCT NCT07500090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07500090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH) Followed by an Open-label Extension
Lead sponsor
Harmony Biosciences Management, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
March 16, 2026
Completion date
October 31, 2028
Enrollment
248 (estimated)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic hypersomnia